NASDAQ:CRIS - Curis Stock Price, Forecast & News

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Curis's stock reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.19) EPS for the quarter. The biotechnology company had revenue of $2.86 million for the quarter. View Curis' Earnings History.

Curis is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Curis.

Media headlines about CRIS stock have been trending extremely negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Curis earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Curis.

Curis saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 189,000 shares, a decline of 49.0% from the October 31st total of 370,800 shares. Based on an average daily trading volume, of 150,300 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.7% of the company's shares are sold short. View Curis' Current Options Chain.

Some companies that are related to Curis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), Zynga (ZNGA), Synergy Pharmaceuticals (SGYP), Jones Energy (JONE), CTI BioPharma (CTIC), Agenus (AGEN) and Idera Pharmaceuticals (IDRA).

Curis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (3.74%), Arnhold LLC (1.25%), BB&T Securities LLC (0.13%) and Sunbelt Securities Inc. (0.04%). Company insiders that own Curis stock include James E Dentzer, Kenneth I Kaitin and Robert Martell. View Institutional Ownership Trends for Curis.

CRIS stock was sold by a variety of institutional investors in the last quarter, including Arnhold LLC. Company insiders that have sold Curis company stock in the last year include James E Dentzer, Kenneth I Kaitin and Robert Martell. View Insider Buying and Selling for Curis.

CRIS stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, BB&T Securities LLC and Sunbelt Securities Inc.. View Insider Buying and Selling for Curis.

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRIS stock can currently be purchased for approximately $1.57.

Curis has a market capitalization of $52.13 million and generates $10.43 million in revenue each year. Curis employs 55 workers across the globe.View Additional Information About Curis.

The official website for Curis is http://www.curis.com/.

Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]